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Abstract
Background: The current recommended therapy for diffuse coccidioidal pneumonia involves
initial treatment with amphotericin B deoxycholate or high-dose fluconazole, followed by an azole
after clinical improvement. Amphotericin B is more frequently used as initial therapy if the patient's
deterioration is rapid.
Case presentation: A 31-year-old Korean male with coccidioidomycosis presented to the
hospital with miliary infiltrates on chest X-ray (CXR) and skin rash on the face and trunk. Initially,
the patient did not respond to amphotericin B deoxycholate therapy. However, following
caspofungin and fluconazole combination therapy, the patient showed favourable radiological,
serological, and clinical response.
Conclusion: This appears to be the first case of diffuse coccidioidal pneumonia with skin
involvement in an immunocompetent patient who was treated successfully with caspofungin and
fluconazole. Combination therapy with caspofungin and fluconazole may, therefore, be an
alternative treatment for diffuse coccidioidal pneumonia that does not respond to amphotericin B
deoxycholate therapy.
Background
Coccidioidomycosis is an infection caused by inhalation
of dimorphic fungi of the genus Coccidioides (C. immitis
and C. posadasii). It is endemic in desert regions of the
southwestern United States, Central America and South
America. This infection has protean manifestations and is
frequently misdiagnosed, especially in persons who travel
to endemic areas and return to locations where the disease
is not typically encountered [1].
Diffuse coccidioidal pneumonia is an unusual complica-
tion of a primary pulmonary infection in an immuno-
competent patient. It has been associated with a high
mortality [1,2]. Diffuse bilateral pulmonary infiltrates
may be a result of a hematogenous spread. They may also
be a result of a multiple foci of infection secondary to high
innoculum exposure. In either case, even early infections
are regarded as serious enough to warrant therapy [3]. The
recommended therapy for diffuse coccidioidal pneumo-
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Chest X-ray (CXR) and high-resolution computed tomography (CT) findings on admission, and again at five months following combined treatmentFigure 1
Chest X-ray (CXR) and high-resolution computed tomography (CT) findings on admission, and again at five 
months following combined treatment. Top (on admission): (A) Posterior-anterior chest radiograph (P-A CXR) shows 
multiple tiny reticular nodules on both lungs; (B) Tiny centrilobular and subpleural nodules are evident in both lungs on the 
chest CT. Bottom (five months after combined treatment): (C) A follow-up CXR shows improvement in the multiple reticu-
lar nodules; (D) A follow-up CT scan reveals the improvement of the residual nodules.
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antifungal after clinical improvement [4,5]. Recently,
updated guidelines recommend high-dose fluconazole or
amphotericin B for the treatment of diffuse coccidioidal
pneumonia [6]. Although amphotericin B is frequently
used as initial therapy, the disease remains difficult to
treat and is often characterized by frequent treatment fail-
ure and disease relapse. Newly available antifungal agents
include voriconazole, posaconazole and caspofungin,
each of which may play a role in the treatment of refrac-
tory coccidioidosis [4].
Here, we present the case of an immunocompetent
patient with diffuse coccidioidal pneumonia who
responded to caspofungin and fluconazole therapy with-
out experiencing any adverse effects.
Case presentation
On October 6, 2004, a 31-year-old Korean male was
admitted to the hospital with a fever, chills, general
fatigue, cough, dyspnea, night sweats, and a weight loss of
2 kg, all of which he had experienced over the previous
four weeks. The patient had smoked half a packet of ciga-
rettes per day for the past 10 years and had been diag-
nosed four years previously with adrenoleukodystrophy.
During August and September of 2004, the patient trav-
elled to Corona, California. The symptoms began while at
this location, and he was subsequently treated for bacte-
rial pneumonia at an area hospital. However, his symp-
toms worsened rapidly and he returned to Korea.
On admission to the hospital, the following vital signs
were observed: temperature, 37.8°C; blood pressure, 130/
70 mmHg; pulse, 92 beats/min; and respiratory rate, 24
breaths/min. A clinical examination revealed a moder-
ately ill-appearing male with multiple, encrusted, ery-
thematous, papular nodules on the face and trunk. There
were no other remarkable findings on examination. Labo-
ratory tests revealed leukocytosis with eosinophilia (white
blood cell count 23,460 cells/µl; eosinophils 22%), an
increased erythrocyte sedimentation rate (100 mm/h),
and increased levels of C-reactive protein (24.7 mg/dl). A
chest X-ray (CXR) and computerized tomography (CT)
scan revealed tiny, multiple nodules in both lung fields
(Figure 1, top). Sputum acid-fast bacillus stain and tuber-
culosis culture were both negative. The patient underwent
a bronchoscopy and a skin punch biopsy. The biopsy
revealed the presence of a chronic granuloma with thick-
walled, mature spherules containing endospores. A subse-
quent skin tissue culture grew Coccidioides immitis. The
patient's serum complement fixation (CF) titre was 1:16,
and a serum coccidioidal immunodiffusion test for IgG
antibody was negative. (All coccidioidal CF antibody test-
ing was carried out at the laboratory of Lynn A. Cheryk,
Mayo Clinic, Minnesota, USA). Cerebrospinal fluid (CSF)
showed no evidence of meningitis.
The patient was diagnosed with diffuse coccidioidal pneu-
monia with skin involvement and was treated with
amphotericin B deoxycholate (total dosage, 1970 mg; ~1
mg/kg) for 40 days (day five to day 45 of hospitalization).
However, the patient still complained of night sweats and
a cough. Physical examination revealed a persistent fever
(temperature of 38.6–39°C) and no improvement of the
skin rash. His general condition progressively deterio-
rated. The patient developed a right pleural effusion and
miliary shadows on the CXR did not improve. A follow-up
CF titre performed on day 27 of hospitalization had
increased to 1:64. On day 45 of hospitalization, the ther-
apy was changed to caspofungin (initially 70 mg and then
50 mg/day, given intravenously) and fluconazole (400
mg/day, given orally). Sixteen days after the combination
treatment (day 60 of hospitalization), a CXR revealed a
reduction in both the miliary nodes and the pleural effu-
sion. The patient improved initially, developing only
occasional fevers. Forty-nine days after the combination
therapy, the patient's peak body temperature fell below
38°C, and the dyspnea had subsided. The serum CF anti-
body titre had decreased to 1:8. However, the cough
remained. By day 125 of the combination treatment, the
patient had defervesced, and all of his respiratory symp-
toms subsided. Although some skin lesions still remained
on his face, most were nearly resolved. The serum CF anti-
body titre was undetectable, and on day 131, caspofungin
therapy was discontinued. The patient was subsequently
treated with only fluconazole at a dose of 400 mg/day.
There were no drug-related side effects noted from the use
of the caspofungin and fluconazole. On day 194, his fol-
low-up CF antibody titre increased to 1:256. However, the
patient did not experience respiratory symptoms, develop
a skin rash, or develop abnormalities on CXR. A follow-up
examination five months following completion of the
combination treatment revealed minimal residual nod-
ules visible on CXR and CT scan (Figure 1, bottom). The
patient's CF antibody titre was 1:128. As of September
2005, the patient was clinically healthy and without any
respiratory symptoms and/or fevers. However, he is still
receiving suppressive treatment with fluconazole.
Discussion
In 2000, the Infectious Diseases Society of America
(IDSA) published guidelines for the treatment of coccidi-
oidomycosis [5]. Amphotericin B was recommended as
first-line therapy for diffuse pneumonia caused by Coccid-
ioides organisms. Despite the use of amphotericin B ther-
apy, diffuse coccidioidal pneumonia remains difficult to
treat, and a patient's course is often characterized by fre-
quent treatment failure and disease relapse.Page 3 of 5
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evaluated for their activity against C. immitis, in both in
vitro and in vivo studies. Agents that have been shown to
be potentially useful in the treatment of coccidioidomyco-
sis include voriconazole, caspofungin, and posaconazole
[4,7-9].
Lutz et al. [9] published in vitro data for posaconazole
showing fair fungicidal activity against C. immitis. They
also noted that posaconazole showed superior activity to
fluconazole or itraconazole in a murine model of dissem-
inated non-meningeal coccidioidomycosis. Anstead et al.
[7] reported a successful outcome in six patients treated
with posaconazole who were refractory to refractory to
conventional antifungal therapies. Another recent report
described the successful treatment with voriconazole in a
human with disseminated non-meningeal coccidioid-
omycosis [8]. However, both posaconazole and voricona-
zole were not available for treatment of this particular
patient.
Caspofungin is the first of a new class of antifungal agents,
the echinocandins, which target the fungal cell wall itself
via interruption of the β-(1,3)-D-glucan synthesis path-
way [10,11]. This mechanism of action is different from
that of amphotericin B and azoles. β-(1,3)-D-glucan syn-
thase is absent from mammalian cells. Caspofungin has
received US Food and Drug Administration approval for
the treatment of mucosal and invasive candidiasis, and
also for salvage therapy of invasive aspergillosis [10].
Caspofungin was therapeutically effective in a murine
model of C. immitis infection [12], despite its limited in
vitro activity against the fungus when minimum inhibi-
tory concentrations (MICs) were determined. However,
an improved correlation between in vivo activity and the
minimum effective concentration (MEC) – the lowest
dose of drug that causes morphologic effects on fungal
hyphae – was observed [12]. In this study, mice infected
with one of two strains of C. immitis (each with an MEC of
0.125 mg/mL but one with an MIC of 8 mg/mL and the
other with an MIC of 64 mg/L) responded equally well to
treatment with caspofungin. One recent report describes
the successful treatment of disseminated coccidioidomy-
cosis in a renal transplant recipient with caspofungin [13].
Furthermore, another report describes a coccidioidal
meningitis treatment failure in which caspofungin was
not detected in CSF, even though it was found to be above
MIC in his serum [14]. We think that the limited CSF pen-
etration of caspofungin may be due to the large molecular
mass, water solubility, and high protein binding of caspo-
fungin [10].
Amphotericin B therapy failed to prevent disease progres-
sion in our patient. At the time of initial treatment, the
recommended regime consisted of treatment with
amphotericin B, followed by an azole if clinical improve-
ment was achieved [4,5]. The only new antifungal agent
available to us was caspofungin. Since clinical and in vitro
data for caspofungin were limited, caspofungin mono-
therapy could not be selected because of the severity of the
illness. The scarcity of evidence of in vitro antagonism
when combined with other antifungal agents led us to
consider combination therapy [10]. We considered fluco-
nazole or itraconazole as a combination antifungal with
caspofungin. We chose fluconazole because itraconazole
has absorption problems and we would be unable to
measure serum levels of itraconazole. Combined treat-
ment against C. immitis is currently not recommended,
and the possibility of antagonism or synergism between
caspofungin and fluconazole has not yet been fully evalu-
ated. However, an in vitro study reported that although
synergy was low between caspofungin and fluconazole,
synergism was the pattern most often observed [15]. The
mechanisms proposed for its synergy may be simultane-
ous inhibition of different fungal cell targets, such as the
cell wall and membrane targets.
This data, the limited treatment options, and the severity
of the illness prompted us to carry out a trial of combined
therapy with caspofungin and fluconazole. At the time of
this report, the updated IDSA guidelines published in Sep-
tember 2005 recommended amphotericin B or high-dose
fluconazole for the treatment of diffuse coccidioidal
pneumonia [6]. The high-dose fluconazole therapy was
not recommended when our patient was treated.
On day 16 after initiating combined therapy with caspo-
fungin and fluconazole, a CXR revealed a reduction in
both the multiple tiny reticular nodules and the pleural
effusion. The patient began to improve clinically, even
though the CF antibody titre increased from an undetect-
able level to 1:128 after completion of combined therapy.
The CF titre is considered a prognostic factor. However,
our patient was clinically healthy: the skin rash had sub-
sided, and the chest CT showed improvement. Thus, we
did not perform any further evaluations. An initial bone
scan and CSF analysis showed no abnormalities. The
patient did not complain of a headache or localized pain.
Over the course of this study, the patient was carefully
monitored, and he will continue to receive fluconazole for
the foreseeable future.
Combination therapy with caspofungin and fluconazole
may be an alternative treatment for diffuse coccidioidal
pneumonia with non-meningeal extrapulmonary
involvement that is unresponsive to amphotericin B ther-
apy. However, determining the best course of therapy
remains a challenge. Further clinical studies evaluating
this combination are required.Page 4 of 5
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Although combined therapy with caspofungin and fluco-
nazole against C. immitis is not currently recommended, it
may represent an alternative treatment for cases that do
not respond to amphotericin B deoxycholate.
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